Levine James E.
SEC insider (Form 3/4/5 filer). CIK 0001463151. Chief Financial Officer at KAZIA THERAPEUTICS LTD (KZIA) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 19, 2026. Located in SYDNEY.
Companies Levine James E. has filed insider reports for
- KAZIA THERAPEUTICS LTD (KZIA): Officer, Chief Financial Officer
- Cardiff Oncology, Inc. (CRDF): Officer, Chief Financial Officer
Levine James E.
CIK: 0001463151
Transaction Breakdown
Open Market Buys (P)3 (60.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 19, 2026KZIA
KAZIA THERAPEUTICS LTD
AwardDirectEmployee Stock Option (right to buy)
200K shares- - Mar 11, 2025CRDF
Cardiff Oncology, Inc.
AwardDirectStock Options
332.6K shares- - Dec 18, 2024CRDF
Cardiff Oncology, Inc.
PurchaseIndirect2.4K shares at avg. $5.00$12K - Dec 17, 2024CRDF
Cardiff Oncology, Inc.
PurchaseIndirect2.8K shares at avg. $5.42$15K - Dec 16, 2024CRDF
Cardiff Oncology, Inc.
PurchaseIndirect2.6K shares at avg. $3.83$10K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 19, 2026 |  KZIA KAZIA THERAPEUTICS LTD | Award Employee Stock Option (right to buy) | 200,000 | - | - | Direct |
| Mar 11, 2025 |  CRDF Cardiff Oncology, Inc. | Award Stock Options | 332,621 | - | - | Direct |
| Dec 18, 2024 | CRDF Cardiff Oncology, Inc. | Purchase | 2,400 | $5.00 | $12,000 | Indirect |
| Dec 17, 2024 | CRDF Cardiff Oncology, Inc. | Purchase | 2,752 | $5.42 | $14,905 | Indirect |
| Dec 16, 2024 | CRDF Cardiff Oncology, Inc. | Purchase | 2,564 | $3.83 | $9,820 | Indirect |
1-5 of 5 transactions